PPIB and steatosis: Given our earlier findings that pan-cyclophilin inhibition via CRV431 or NV556 both reduced fibrosis and HCC development, but not necessarily other characteristics of NAFLD/NASH such as steatosis or inflammation, this finding was unexpected, but likely reflects differences in the loss of function models we tested.